A new study published in Nature Medicine by the University of San Antonio Health Center and researchers at the University of Florida research shows that they have found a safe and effective next-generation drug for treating multiple types of leukemia and lymphoma in adults and children. “This is a new drug called PROTAC, which targets a basic survival protein called BCL-XL in cancer cells,” the researchers said.
Previous drugs for BCL-XL have dangerously reduced platelets and have a high risk of bleeding. But our drugs significantly reduce this risk and may be more useful in cancer patients. “
‘The PROTAC we studied will treat T-cell malignancies, such as T-cell acute leukemia and T-cell lymphoma,’ said Robert Hromas, a prominent hematologist and oncologist and one of the study’s authors.
T cells are produced by the upper thymus, which are important participants in the body’s immune response. When they become cancer cells, they rely on BCL-XL to survive.
Several co-authors from the Greene Child Cancer Institute at the University of San Antonio Health Center published the paper with Dr. Hromas.
Dr Peter Houghton, one of the study’s authors and director of the Greeley Institute, said: “ProTAC drugs can degrade the BCL-XL protein, not just inhibit it, and will be developed for some incurable childhood cancers.” “